News

Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford ...
Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a new push to ...
Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...
What happens when data projects forget the people who use them? A Disconnect. Boehringer Ingelheim turned things around by ...
Germany’s Boehringer Ingelheim has selected a third drug candidate to move forward into IND-enabling studies under its ongoing collaboration with Oxford BioTherapeutics.
Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies Provided by GlobeNewswire Jul 3, 2025, 12:00:00 AM ...
The OBT-Boehringer partnership began in 2013 and has expanded through subsequent agreements in 2020 and 2022 to include additional programs. The collaboration has yielded multiple development-stage ...
The site was created by Boehringer Ingelheim after a survey identified knowledge gaps among owners on many health topics ...
Boehringer Ingelheim Greece, alongside its partners, is addressing this issue with the 'Sailboat for Health' initiative. This floating medical facility embarks on annual voyages to deliver ...